Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
City of Hope Medical Center
Fred Hutchinson Cancer Center
Mayo Clinic
Roswell Park Cancer Institute
Vanderbilt-Ingram Cancer Center
University of Washington
Beidahuang Industry Group General Hospital
University of Michigan Rogel Cancer Center
University of Colorado, Denver